Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Gynecology

  Free Subscription


Articles published in Br J Cancer

Retrieve available abstracts of 59 articles:
HTML format
Text format



Single Articles


    May 2017
  1. PLAYDON MC, Nagle CM, Ibiebele TI, Ferrucci LM, et al
    Pre-diagnosis diet and survival after a diagnosis of ovarian cancer.
    Br J Cancer. 2017 May 2. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    April 2017
  2. DICKIE BR, Rose CJ, Kershaw LE, Withey SB, et al
    The prognostic value of dynamic contrast-enhanced MRI contrast agent transfer constant Ktrans in cervical cancer is explained by plasma flow rather than vessel permeability.
    Br J Cancer. 2017 Apr 27. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  3. VIVIANO M, Catarino R, Jeannot E, Boulvain M, et al
    Self-sampling to improve cervical cancer screening coverage in Switzerland: a randomised controlled trial.
    Br J Cancer. 2017 Apr 20. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  4. DURAN GE, Wang YC, Moisan F, Francisco EB, et al
    Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition.
    Br J Cancer. 2017 Apr 11. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    March 2017
  5. GORANOVA T, Ennis D, Piskorz AM, Macintyre G, et al
    Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium.
    Br J Cancer. 2017 Mar 30. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  6. DIXON SC, Nagle CM, Wentzensen N, Trabert B, et al
    Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium.
    Br J Cancer. 2017 Mar 28. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  7. PHELPS DL, Borley JV, Flower KJ, Dina R, et al
    Methylation of MYLK3 gene promoter region: a biomarker to stratify surgical care in ovarian cancer in a multicentre study.
    Br J Cancer. 2017 Mar 28. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  8. BEGG CB, Rice MS, Zabor EC, Tworoger SS, et al
    Examining the common aetiology of serous ovarian cancers and basal-like breast cancers using double primaries.
    Br J Cancer. 2017 Mar 23. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  9. FALLOWFIELD L, Solis-Trapala I, Menon U, Langridge C, et al
    The effect of ovarian cancer screening on sexual activity and functioning: results from the UK collaborative trial of ovarian cancer screening RCT.
    Br J Cancer. 2017 Mar 21. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  10. SHATHASIVAM P, Kollara A, Spybey T, Park S, et al
    VEPH1 expression decreases vascularisation in ovarian cancer xenografts and inhibits VEGFA and IL8 expression through inhibition of AKT activation.
    Br J Cancer. 2017 Mar 16. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    February 2017
  11. KIM SJ, Rosen B, Fan I, Ivanova A, et al
    Epidemiologic factors that predict long-term survival following a diagnosis of epithelial ovarian cancer.
    Br J Cancer. 2017 Feb 16. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  12. PARK YM, O'Brien KM, Zhao S, Weinberg CR, et al
    Gestational diabetes mellitus may be associated with increased risk of breast cancer.
    Br J Cancer. 2017 Feb 16. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  13. NUNES N, Ambler G, Foo X, Naftalin J, et al
    Comparison of two protocols for the management of asymptomatic postmenopausal women with adnexal tumours - a randomised controlled trial of RMI/RCOG vs Simple Rules.
    Br J Cancer. 2017 Feb 2. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    January 2017
  14. LINDEMANN K, Gibbs E, Avall-Lundqvist E, dePont Christensen R, et al
    Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist).
    Br J Cancer. 2017 Jan 24. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  15. KAR SP, Adler E, Tyrer J, Hazelett D, et al
    Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci.
    Br J Cancer. 2017 Jan 19. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  16. HEUDEL PE, Fabbro M, Roemer-Becuwe C, Kaminsky MC, et al
    Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group.
    Br J Cancer. 2017 Jan 10. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    December 2016
  17. KOMMOSS S, Kommoss F, Diebold J, Lax S, et al
    Better resource utilisation and quality of care for ovarian cancer patients using internet-based pathology review.
    Br J Cancer. 2016 Dec 22. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  18. COOK LS, Pestak CR, Leung AC, Steed H, et al
    Combined oral contraceptive use before the first birth and epithelial ovarian cancer risk.
    Br J Cancer. 2016 Dec 13. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  19. LICAJ I, Jacobsen BK, Selmer RM, Maskarinec G, et al
    Smoking and risk of ovarian cancer by histological subtypes: an analysis among 300 000 Norwegian women.
    Br J Cancer. 2016 Dec 13. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    November 2016
  20. MURPHY N, Xu L, Zervoudakis A, Xue X, et al
    Reproductive and menstrual factors and colorectal cancer incidence in the Women's Health Initiative Observational Study.
    Br J Cancer. 2016 Nov 29. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  21. SAMUELS S, Balint B, von der Leyen H, Hupe P, et al
    Precision medicine in cancer: challenges and recommendations from an EU-funded cervical cancer biobanking study.
    Br J Cancer. 2016 Nov 22. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  22. LI X, Chen W, Zeng W, Wan C, et al
    microRNA-137 promotes apoptosis in ovarian cancer cells via the regulation of XIAP.
    Br J Cancer. 2016 Nov 22. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  23. CHAUDARY N, Pintilie M, Hedley D, Hill RP, et al
    Hedgehog inhibition enhances efficacy of radiation and cisplatin in orthotopic cervical cancer xenografts.
    Br J Cancer. 2016 Nov 22. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  24. COLDMAN AJ, Gondara L, Smith LW, van Niekerk D, et al
    Disease detection and resource use in the safety and control arms of the HPV FOCAL cervical cancer screening trial.
    Br J Cancer. 2016 Nov 17. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  25. MIYAMOTO M, Takano M, Iwaya K, Shinomiya N, et al
    High-temperature-required protein A2 as a predictive marker for response to chemotherapy and prognosis in patients with high-grade serous ovarian cancers.
    Br J Cancer. 2016 Nov 10. doi: 10.1038/bjc.2016.
    PubMed     Text format    


  26. LEDERMANN JA, Harter P, Gourley C, Friedlander M, et al
    Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer.
    Br J Cancer. 2016 Nov 8. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  27. OULDAMER L, Bendifallah S, Body G, Touboul C, et al
    Predicting poor prognosis recurrence in women with endometrial cancer: a nomogram developed by the FRANCOGYN study group.
    Br J Cancer. 2016 Nov 8. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    October 2016
  28. BLINMAN P, Mileshkin L, Khaw P, Goss G, et al
    Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial.
    Br J Cancer. 2016 Oct 20. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  29. ZAAIJER LH, van Doorn HC, Mourits MJ, van Beurden M, et al
    Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers.
    Br J Cancer. 2016 Oct 18. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  30. KONECNY GE, Kristeleit RS
    PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions.
    Br J Cancer. 2016 Oct 13. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  31. ORBO A, Arnes M, Lysa LM, Borgfeldt C, et al
    HE4 is a novel tissue marker for therapy response and progestin resistance in medium- and low-risk endometrial hyperplasia.
    Br J Cancer. 2016 Oct 6. doi: 10.1038/bjc.2016.
    PubMed     Text format    


  32. SHAFRIR AL, Babic A, Tamimi RM, Rosner BA, et al
    Reproductive and hormonal factors in relation to survival and platinum resistance among ovarian cancer cases.
    Br J Cancer. 2016 Oct 4. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    September 2016
  33. HUANG J, Mondul AM, Weinstein SJ, Koutros S, et al
    Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Br J Cancer. 2016 Sep 27. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  34. LANDY R, Pesola F, Castanon A, Sasieni P, et al
    Impact of cervical screening on cervical cancer mortality: estimation using stage-specific results from a nested case-control study.
    Br J Cancer. 2016 Sep 15. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  35. DONAT-VARGAS C, Akesson A, Berglund M, Glynn A, et al
    Dietary exposure to polychlorinated biphenyls and risk of breast, endometrial and ovarian cancer in a prospective cohort.
    Br J Cancer. 2016 Sep 15. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  36. KOMMOSS S, Gilks CB, du Bois A, Kommoss F, et al
    Ovarian carcinoma diagnosis: the clinical impact of 15 years of change.
    Br J Cancer. 2016 Sep 15. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  37. QIN B, Moorman PG, Alberg AJ, Barnholtz-Sloan JS, et al
    Dairy, calcium, vitamin D and ovarian cancer risk in African-American women.
    Br J Cancer. 2016 Sep 15. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    August 2016
  38. YANG Z, Wang XL, Bai R, Liu WY, et al
    miR-23a promotes IKKalpha expression but suppresses ST7L expression to contribute to the malignancy of epithelial ovarian cancer cells.
    Br J Cancer. 2016 Aug 18. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  39. ORBO A, Arnes M, Lysa LM, Borgfelt C, et al
    HE4 is a novel tissue marker for therapy response and progestin resistance in medium- and low-risk endometrial hyperplasia.
    Br J Cancer. 2016 Aug 18. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  40. FRUSCIO R, Ceppi L, Corso S, Galli F, et al
    Long-term results of fertility-sparing treatment compared with standard radical surgery for early-stage epithelial ovarian cancer.
    Br J Cancer. 2016 Aug 18. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  41. VAN DER PUTTEN LJ, Visser NC, van de Vijver K, Santacana M, et al
    L1CAM expression in endometrial carcinomas: an ENITEC collaboration study.
    Br J Cancer. 2016 Aug 9. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  42. BRONGER H, Singer J, Windmuller C, Reuning U, et al
    CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer.
    Br J Cancer. 2016 Aug 4. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  43. MAGGINO T, Sciarrone R, Murer B, Dei Rossi MR, et al
    Screening women for cervical cancer carcinoma with a HPV mRNA test: first results from the Venice pilot program.
    Br J Cancer. 2016 Aug 4. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  44. SAYASNEH A, Ferrara L, De Cock B, Saso S, et al
    Evaluating the risk of ovarian cancer before surgery using the ADNEX model: a multicentre external validation study.
    Br J Cancer. 2016 Aug 2. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    July 2016
  45. JONES ME, Schoemaker MJ, Wright L, McFadden E, et al
    Menopausal hormone therapy and breast cancer: what is the true size of the increased risk?
    Br J Cancer. 2016 Jul 28. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  46. VAIDYANATHAN A, Sawers L, Gannon AL, Chakravarty P, et al
    ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells.
    Br J Cancer. 2016 Jul 14. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  47. LUTTMER R, De Strooper LM, Dijkstra MG, Berkhof J, et al
    FAM19A4 methylation analysis in self-samples compared with cervical scrapes for detecting cervical (pre)cancer in HPV-positive women.
    Br J Cancer. 2016 Jul 14. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    June 2016
  48. COCCO E, Lopez S, Black J, Bellone S, et al
    Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo.
    Br J Cancer. 2016 Jun 28. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  49. STAFF S, Aaltonen M, Huhtala H, Pylvanainen K, et al
    Endometrial cancer risk factors among Lynch syndrome women: a retrospective cohort study.
    Br J Cancer. 2016 Jun 23. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  50. COFFEY K, Gaitskell K, Beral V, Canfell K, et al
    Past cervical intraepithelial neoplasia grade 3, obesity, and earlier menopause are associated with an increased risk of vulval cancer in postmenopausal women.
    Br J Cancer. 2016 Jun 23. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  51. CANNIOTO RA, LaMonte MJ, Kelemen LE, Risch HA, et al
    Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium.
    Br J Cancer. 2016 Jun 14. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  52. WANG C, Winterhoff BJ, Kalli KR, Block MS, et al
    Expression signature distinguishing two tumour transcriptome classes associated with progression-free survival among rare histological types of epithelial ovarian cancer.
    Br J Cancer. 2016 Jun 2. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    May 2016
  53. DREW Y, Ledermann J, Hall G, Rea D, et al
    Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
    Br J Cancer. 2016 May 26. doi: 10.1038/bjc.2016.
    PubMed     Text format    


  54. KAMPJARVI K, Makinen N, Mehine M, Valipakka S, et al
    MED12 mutations and FH inactivation are mutually exclusive in uterine leiomyomas.
    Br J Cancer. 2016 May 17. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    March 2016
  55. BROWN JS, Kaye SB, Yap TA
    PARP inhibitors: the race is on.
    Br J Cancer. 2016;114:713-5.
    PubMed     Text format    


  56. RATNER ES, Zhu YL, Penketh PG, Berenblum J, et al
    Triapine potentiates platinum-based combination therapy by disruption of homologous recombination repair.
    Br J Cancer. 2016;114:777-86.
    PubMed     Text format     Abstract available


  57. PALMER TJ, McFadden M, Pollock KG, Kavanagh K, et al
    HPV immunisation and cervical screening-confirmation of changed performance of cytology as a screening test in immunised women: a retrospective population-based cohort study.
    Br J Cancer. 2016;114:582-9.
    PubMed     Text format     Abstract available


    January 2016
  58. PALMER TJ, McFadden M, Pollock KG, Kavanagh K, et al
    HPV immunisation and increased uptake of cervical screening in Scottish women; observational study of routinely collected national data.
    Br J Cancer. 2016 Jan 21. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


    December 2015
  59. MURRAY MJ, Bell E, Raby KL, Rijlaarsdam MA, et al
    A pipeline to quantify serum and cerebrospinal fluid microRNAs for diagnosis and detection of relapse in paediatric malignant germ-cell tumours.
    Br J Cancer. 2015 Dec 15. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Gynecology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: